Due to health issues, this site is no longer maintained and will be shut down shortly. |
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
$30.51 +0.12 (0.40%)
As of 03/27/2023 14:07:44 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.